|
|
Post by joeypotsandpans on May 23, 2022 13:22:41 GMT -5
One approved drug was the ice breaker, two approved drugs removes any doubt about the validity of Technosphere and paves a path to profitability and future growth. Mike pushed the boulder to the top of the hill with Martine's help, it should be rolling down full steam ahead from here, congrats to the long term holders, peppy should be updating some pretty nice price targets going forward 😉👍🏻
|
|
|
|
Post by scottmnkd on May 23, 2022 13:34:40 GMT -5
One approved drug was the ice breaker, two approved drugs removes any doubt about the validity of Technosphere and paves a path to profitability and future growth. Mike pushed the boulder to the top of the hill with Martine's help, it should be rolling down full steam ahead from here, congrats to the long term holders, peppy should be updating some pretty nice price targets going forward 😉👍🏻 Yes. I truely believe that today is the day it all changes. |
|
|
|
Post by bthomas55ep on May 23, 2022 13:43:15 GMT -5
One approved drug was the ice breaker, two approved drugs removes any doubt about the validity of Technosphere and paves a path to profitability and future growth. Mike pushed the boulder to the top of the hill with Martine's help, it should be rolling down full steam ahead from here, congrats to the long term holders, peppy should be updating some pretty nice price targets going forward 😉👍🏻 Would be nice to see another UTHR molecule announced on the heels of the Tyvasso approval. Better yet, a 10% equity taken by UTHR at a $5 Billion valuation to get things rolling! Congratulations. |
|
|
|
Post by Chris-C on May 24, 2022 1:24:04 GMT -5
The naysayers and boo birds will hang around because that's what they do. No matter. They are as irrelevant now as they were yesterday. Onward. Congratulations and good luck to long-suffering decade-long investors. Patience and conviction are rewarded. Know what yøu own.
Still a bargain.
|
|
|
|
Post by akemp3000 on May 24, 2022 5:44:16 GMT -5
It is absolutely a bargain. The company is still trading in the "penny stock" range which some recognize as being $5 or less per share. Many institutional investors are prohibited from investing in penny stocks under $5. With this approval and the now expected forthcoming revenues, there is no reason whatsoever this company should be trading in the penny stock range. That should change in the coming days as analysts announce their upgrades and most assuredly by the time UTHR revenue appears. Not sure I've ever seen such a slam dunk investment but that's been the mantra for a long time with this company. Glad to see it's finally coming to fruition.
|
|
